Artivion Inc. logo

Artivion Inc. (AORT)

Market Closed
17 Jul, 20:00
NYSE NYSE
$
25. 06
-0.67
-2.604%
$
1.17B Market Cap
- P/E Ratio
0.12% Div Yield
535,300 Volume
- Eps
$ 25.73
Previous Close
Add Transaction
Day Range
24.79 25.85
Year Range
19.16 48.25
Want to track AORT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

AORT closed today lower at $25.06, a decrease of -2.604% from yesterday's close, completing a monthly increase of 8.7202% or $2.01. Over the past 12 months, AORT stock lost -44.6677%.
AORT pays dividends to its shareholders, with the most recent payment made on Dec 18, 2015. The next estimated payment will be in 18 Mar 2016 on Mar 18, 2016 for a total of $0.03.
The last earnings report, released on Apr 30, 2026, missed the consensus estimates by -0.042%. On average, the company has surpassed earnings expectations by 0.068%, based on the last three reports.
Artivion Inc. has completed 2 stock splits, with the recent split occurring on Dec 28, 2000.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on NYSE (USD).

AORT Chart

People also search for

Nuvation Bio Inc.
$ 5.8
+2.8369%
Butterfly Network, Inc.
$ 6.62
-5.5635%
Teladoc Health Inc.
$ 9.43
-0.4224%
Biohaven Ltd.
$ 15.44
+8.9626%
Inspire Medical Systems, Inc.
$ 50.6
-1.8238%
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device

Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device

AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.

Zacks | 2 weeks ago
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript

Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript

Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 months ago
Artivion Q1 Earnings Call Highlights

Artivion Q1 Earnings Call Highlights

Artivion NYSE: AORT executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due primarily to softer stent graft trends and timing around U.S. AMDS account stocking.

Marketbeat | 2 months ago

Artivion Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
CE
Curtis Ellergodt Rothschild Investment LLC
126 $3,551.63 $3,034.08 -$517.55 -14.57%
SN
Stephanie Nee HARBOR CAPITAL ADVISORS Inc.
130 $5,458.44 $3,109.6 -$2,348.84 -43.03%
BG
Bart Gancher Intech Investment Management LLC
13,620 $621,208.2 $326,199 -$295,009.2 -47.49%
Juniper Investment Company
Juniper Investment Company Juniper Investment Company LLC
1.19M $28.21M $28.48M $271,155.69 0.96%
MD
Michelle Dubey Yousif Capital Management LLC
11,327 $232,488.11 $275,359.37 $42,871.26 18.44%

Artivion Inc. (AORT) FAQ

What is the stock price today?

The current price is $25.06.

On which exchange is it traded?

Artivion Inc. is listed on NYSE.

What is its stock symbol?

The ticker symbol is AORT.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.12%.

What is its market cap?

As of today, the market cap is 1.17B.

Has Artivion Inc. ever had a stock split?

Artivion Inc. had 2 splits and the recent split was on Dec 28, 2000.

Artivion Inc. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
James Patrick Mackin CEO
NYSE Exchange
228903100 CUSIP
US Country
1,600 Employees
12 Mar 2014 Last Dividend
28 Dec 2000 Last Split
- IPO Date

Overview

Artivion, Inc., initially known as CryoLife, Inc., before its name change in January 2022, is a prominent entity in the medical devices and implantable human tissues sector, with operations extending globally. Founded in 1984 and based in Kennesaw, Georgia, the company is adept at manufacturing, processing, and distributing a wide array of medical devices. These products are designed for use in various medical procedures, including cardiac, vascular, neurologic, and pulmonary operations. Artivion, Inc. caters to a diverse clientele, including physicians, hospitals, and other healthcare facilities, with its offerings significantly influencing the practices of cardiac, vascular, thoracic, and general surgeons across the world.

Products and Services

  • BioGlue: A unique polymer made from bovine blood protein, used across a range of surgical procedures for protein cross-linking.
  • Cardiac Preservation Services: Specialized services aimed at maintaining cardiac health during surgery.
  • PhotoFix: A bovine pericardial patch favored for its durability and versatility in surgical applications.
  • Aortic Arch Stent Grafts (E-vita Open Plus and E-vita Open Neo): Advanced solutions for complicated aortic surgeries, offering custom-designed options to meet specific patient needs.
  • E-xtra Design Engineering Systems: Tailored engineering solutions for tackling aortic vascular diseases effectively.
  • E-nside: An off-the-shelf stent graft designed for the thoraco-abdominal disease treatment, simplifying complex procedures.
  • E-vita THORACIC 3G: A cutting-edge endovascular solution for thoracic aortic aneurysm treatments, highlighting technological advancements in this field.
  • E-ventus BX: A balloon-expandable peripheral stent graft designed for the precise treatment of renal and pelvic arteries.
  • E-liac and E-tegra: Stent graft systems focused on treating aneurysmal conditions in iliac arteries and infrarenal abdominal aortic aneurysms, respectively, enhancing the range of vascular interventions available.
  • Synthetic Vascular Grafts: Synthetically engineered grafts for open aortic and peripheral vascular surgical procedures, exemplifying the advancements in synthetic biocompatible materials.
  • PerClot: An absorbable powdered hemostat used in various surgical interventions to promote hemostasis efficiently.
  • Cardiac Laser Therapy Products: Innovative solutions for angina treatment, using laser technology to provide relief and improve patient outcomes.
  • CryoVein and CryoArtery: Vascular preservation services for femoral veins and arteries, enhancing the longevity and success rates of vascular surgeries.
  • On-X Prosthetic Heart Valves (Aortic and Mitral) and Ascending Aortic Prosthesis: State-of-the-art artificial heart valves and associated prostheses for cardiac surgery, representing significant achievements in materials science and biomechanics.
  • CarbonAid CO2 Diffusion Catheters and Chord-X ePTFE Sutures: Advanced catheter systems for CO2 management and high-quality sutures for mitral chordal replacement, illustrating the precision manufacturing techniques used in medical devices.
  • Ascyrus Medical Dissection Stents: Specialized stents designed for the treatment of arterial dissections, contributing to safer cardiovascular procedures.
  • Pyrolytic Carbon Coating Services: Specialized services offered to other medical device manufacturers, highlighting Artivion, Inc.’s capacity for innovation and support within the medical device manufacturing industry.

Contact Information

Address: 205 Hudson Street, 7th Floor
Phone: 770 419 3355